Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and concurrent tislelizumab + nimotuzumab + GP/IMRT in high‑risk locally advanced nasopharyngeal carcinoma
ChiCTR2400084470Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Complete Response Rate (CR) after induction therapy. Started May 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2400084470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084470.